Johnson & Johnson, ICOTYDE, Icotrokinra, Plaque Psoriasis, Phase 3 Clinical Trial, ICONIC-LEAD, IL-23 Receptor, Dermatology, Oral Peptide Therapy, Skin Clearance, Psoriasis Treatment

Spring House, Pennsylvania, USA, October 9, 2026 Johnson & Johnson has announced new two-year clinical results for ICOTYDE® (icotrokinra),...